AOP-208

AOP208, formerly known as LB-208, is an investigational orally administered small-molecule antagonist of the serotonin 1B receptor (HTR1B) developed for oncology by the Austrian company AOP Health together with Leukos Biotech, a spin-off of the Josep Carreras Leukaemia Research Institute in Barcelona. It is described as a first-in-class agent that blocks a particular conformation of the 5-HT1B receptor on cancer stem cells, a target that had not previously been exploited in cancer therapy and that controls metabolic pathways involved in tumour cell survival and treatment resistance. A first-in-human phase 1 trial in relapsed or refractory solid tumours and lymphoma, SERONCO-1, is being run at the Vall d'Hebron Institute of Oncology in Barcelona, and a phase 1/2 trial in relapsed or refractory acute myeloid leukaemia and high-risk myelodysplastic syndrome, SERHEMA-1, began treating patients in 2026. The compound has no approved indication in any jurisdiction, and interim pharmacokinetic data reported in 2026 show dose-dependent exposure without plateau, supporting continued dose escalation.AOP208（原名 LB-208）是一种在研口服小分子 5-羟色胺 1B 受体（HTR1B）拮抗剂，由奥地利 AOP Health 公司与巴塞罗那 Josep Carreras 白血病研究所的衍生企业 Leukos Biotech 联合开发。它被称为首创药物，阻断癌细胞干细胞表面 5-HT1B 受体的特定构象，该靶点此前未在癌症治疗中被利用，且控制着参与肿瘤细胞存活与治疗耐药的代谢通路。一项针对复发或难治性实体瘤与淋巴瘤的首次人体 1 期试验 SERONCO-1 正在巴塞罗那 Vall d'Hebron 肿瘤研究所进行，另一项针对复发或难治性急性髓系白血病与高危骨髓增生异常综合征的 1/2 期试验 SERHEMA-1 已于 2026 年开始治疗患者。该化合物未在任何司法管辖区获批，2026 年报告的过渡性药代动力学数据显示暴露呈剂量依赖且未见平台，支持继续剂量爬坡。

History and development

• The programme's scientific origin lies in work begun in 2012 by Ruth Risueño at the Josep Carreras Leukaemia Research Institute in Barcelona, which demonstrated that the serotonin 1B receptor is key to the survival of leukaemic stem cells, the cells responsible for leukaemia initiation, maintenance and relapse. Because no suitable molecule existed to block that receptor in the relevant cancer-cell conformation, Leukos Biotech implemented a chemical development programme that selected the compound now known as AOP208. The preclinical rationale was published in peer-reviewed studies on the receptor's role in cancer stem cells. This origin in a leukaemia research institute explains why the compound's lead clinical indications are haematological.该项目的科学起源在于 Ruth Risueño 2012 年在巴塞罗那 Josep Carreras 白血病研究所开展的工作，该工作证明 5-羟色胺 1B 受体对白血病干细胞（负责白血病发生、维持与复发的细胞）的存活至关重要。由于不存在能在相关癌细胞构象中阻断该受体的合适分子，Leukos Biotech 实施了一项化学开发项目，选出了如今称为 AOP208 的化合物。临床前依据已发表于该受体在癌细胞干细胞中作用的同行评审研究。这一源于白血病研究所的出身，解释了该化合物为何以血液学为首发临床适应症。
• Leukos Biotech was established as a spin-off of the Josep Carreras Leukaemia Research Institute to translate that stem-cell research into drug candidates, and AOP208, then coded LB-208, was its selected clinical candidate from a compound library generated during the screening programme. In 2022 Leukos Biotech and AOP Health entered into a licensing and collaboration agreement covering AOP208 and the entire compound library generated to identify the candidate. AOP Health holds further development rights and exclusive global commercial rights including the United States, Europe, Korea and Taiwan, with the exclusion of mainland China. The agreement gave a small Austrian rare-disease company control of a first-in-class oncology asset.Leukos Biotech 作为 Josep Carreras 白血病研究所的衍生企业成立，旨在把该干细胞研究转化为药物候选，AOP208（当时代号 LB-208）即筛选项目期间所建化合物库中选出的临床候选。2022 年，Leukos Biotech 与 AOP Health 就 AOP208 及为识别该候选而生成的全部化合物库签订许可与合作协议。AOP Health 持有后续开发权及包括美国、欧洲、韩国与中国台湾在内的独家全球商业权利，中国大陆除外。该协议使一家奥地利罕见病小公司掌控了首创类肿瘤资产。
• The first-in-human study SERONCO-1 was registered with the European Clinical Trials Register as 2023-509532-25-00, a phase 1, first-in-human, dose-escalation and cohort-expansion study in adult patients with relapsed or refractory solid tumours and lymphoma, with a planned enrolment of 57 patients. The trial is sponsored by Leukos Biotech with support from AOP Health, conducted at the early-phase clinical trials unit of the Vall d'Hebron Institute of Oncology in Barcelona, and led by medical oncologist Irene Braña, head of the head and neck tumour group there. It is the only centre in the world conducting this study. First safety and pharmacokinetic results were presented at the European Society for Medical Oncology congress in 2025.首次人体研究 SERONCO-1 以 2023-509532-25-00 之编号注册于欧洲临床试验注册库，是一项针对复发或难治性实体瘤与淋巴瘤成人患者的 1 期首次人体、剂量爬坡与队列扩展研究，计划入组 57 例。试验由 Leukos Biotech 申办、AOP Health 支持，在巴塞罗那 Vall d'Hebron 肿瘤研究所早期临床试验单元开展，由那里的头颈部肿瘤组负责人、肿瘤内科医生 Irene Braña 领导。这是全球唯一开展该研究的中心。首批安全性与药代动力学结果于 2025 年在欧洲肿瘤内科学会年会上报告。
• Funding for SERONCO-1 comes in part from the Spanish Ministry of Science and Innovation through the RETOS public-private collaboration programme, grant CPP2021-008715, a structure designed to share risk between public research institutions and companies. The trial's design escalates the dose progressively in patients with various types of solid tumour, including breast, biliary tract and lung cancer, as a preliminary step to efficacy testing in the most responsive solid tumours and leukaemia. That sequencing mirrors the compound's origin in leukaemia stem-cell biology while testing the broader solid-tumour hypothesis. The Barcelona unit's role as sole site keeps the early pharmacokinetic data tightly controlled.SERONCO-1 的部分资助来自西班牙科学与创新部通过 RETOS 公私合作项目（拨款 CPP2021-008715），该结构旨在让公共研究机构与企业共担风险。试验设计在多种实体瘤（包括乳腺癌、胆道癌与肺癌）患者中逐步爬坡，作为在最敏感的实体瘤与白血病中检验疗效的前置步骤。这一排序与该化合物源于白血病干细胞生物学的出身一致，同时检验更广义的实体瘤假说。巴塞罗那单元作为唯一站点，使早期药代动力学数据受到严格控制。
• On 8 June 2026 AOP Health announced the launch of SERHEMA-1, a phase 1/2 trial of AOP208 in patients with relapsed or refractory acute myeloid leukaemia and high-risk myelodysplastic syndrome, registered as EU CTR 2025-523396-38-00 with a planned enrolment of 60 patients. The trial takes place in specialized centres in Spain and Austria and is sponsored by AOP Health, marking the transition of development leadership from Leukos Biotech to the Austrian company. The first patient began treatment in 2026, extending the programme from solid tumours into the haematological malignancies where the target was originally discovered. AOP Health frames the approach as targeting leukemic stem cells and the tumour microenvironment in the bone marrow niche.2026 年 6 月 8 日，AOP Health 宣布启动 SERHEMA-1，这是一项在复发或难治性急性髓系白血病与高危骨髓增生异常综合征患者中测试 AOP208 的 1/2 期试验，注册号为 EU CTR 2025-523396-38-00，计划入组 60 例。试验在西班牙与奥地利的专门中心开展，由 AOP Health 申办，标志着开发主导权从 Leukos Biotech 移交这家奥地利公司。首例患者于 2026 年开始治疗，把项目从实体瘤扩展到该靶点最初被发现的血液肿瘤领域。AOP Health 将该方法框定为靶向白血病干细胞与骨髓龛中的肿瘤微环境。^[1]

Medical uses

• No indication has been approved in any jurisdiction, and all use is confined to two registered clinical trials. SERONCO-1 treats adults with relapsed or refractory solid tumours and lymphoma after failure of standard therapies, with tumour types including breast, biliary tract and lung cancer among the escalation cohorts. The study is designed to find the active and safe dose of the drug before efficacy testing begins in the most responsive solid tumours and leukaemia. As of the 2026 interim report, dose escalation was continuing, with pharmacokinetics showing dose-dependent exposure without plateau. No recommended phase 2 dose has been established.该化合物未在任何司法管辖区获批，全部使用仅限于两项注册临床试验。SERONCO-1 治疗标准治疗失败的复发或难治性实体瘤与淋巴瘤成人患者，爬坡队列涵盖乳腺癌、胆道癌与肺癌等瘤种。该研究旨在找到药物的活性且安全剂量，之后才在最敏感的实体瘤与白血病中开始疗效检验。截至 2026 年过渡性报告，剂量爬坡仍在继续，药代动力学显示暴露呈剂量依赖且未见平台。尚未确定推荐 2 期剂量。
• SERHEMA-1, the second trial, addresses relapsed or refractory acute myeloid leukaemia and high-risk myelodysplastic syndrome, patient groups with limited treatment options and poor outcomes. The 1/2 期设计 combines safety finding with early efficacy signals, and the planned enrolment of 60 patients reflects the smaller eligible population in these diseases. The choice of haematological indications returns to the target's original biological context, since the serotonin 1B receptor was implicated in leukaemic stem-cell survival. For both trials the therapeutic hypothesis is that blocking the receptor in cancer stem cells removes a survival and resistance mechanism rather than killing bulk tumour cells directly.第二项试验 SERHEMA-1 针对复发或难治性急性髓系白血病与高危骨髓增生异常综合征患者群体，这些患者治疗选择有限、预后差。1/2 期设计把安全性寻找与早期疗效信号结合，60 例的计划入组反映了这些疾病中较小的合格人群。血液学适应症的选择回到该靶点最初的生物学背景，因为 5-羟色胺 1B 受体本就牵涉白血病干细胞存活。对两项试验而言，治疗假说都是阻断癌细胞干细胞中的受体可移除一种存活与耐药机制，而非直接杀伤大部分肿瘤细胞。
• The compound is administered orally, a deliberate convenience for chronic administration in maintenance-like settings, and the dose-escalation design is collecting the pharmacokinetic data needed to set the exposure target. Because the target is a conformation of a receptor that is widely expressed in the normal nervous system, patient selection in the trials does not depend on a tumour biomarker but on the assumption that the cancer-cell conformation is disease-relevant. That assumption is the programme's central bet, and it has not yet been validated by a clinical response. No combination regimen is included in the current protocols.该化合物口服给药，这是为维持治疗式情境中慢性给药的刻意便利，剂量爬坡设计正在收集设定暴露目标所需的药代动力学数据。由于靶点是正常神经系统中广泛表达的受体的一种构象，试验中的患者选择不依赖肿瘤生物标志物，而是基于癌细胞构象与疾病相关的假设。这一假设是该项目的核心赌注，尚未获得临床缓解验证。现行方案不包含联合治疗方案。
• For solid tumours, the escalation cohorts in breast, biliary tract and lung cancer were chosen for their unmet need in the relapsed setting rather than for a biomarker-selected population, and the protocol's language describes them as a preliminary step before efficacy testing in the most responsive tumours. The pipeline also lists solid tumours and lymphomas as the phase 1 indication, with acute myeloid leukaemia and myelodysplastic syndrome as the expansion. Whether the same dose and schedule will serve both solid and haematological disease is an open question that the parallel programme structure will answer. No paediatric or adolescent trial is registered.对实体瘤而言，乳腺癌、胆道癌与肺癌爬坡队列的选择依据是复发情境下的未满足需求，而非生物标志物筛选人群，方案语言将其描述为在最敏感肿瘤中检验疗效前的预备步骤。产品线亦把实体瘤与淋巴瘤列为 1 期适应症，急性髓系白血病与骨髓增生异常综合征为扩展方向。同一剂量与方案能否同时适用于实体瘤与血液学疾病，是并行项目结构将回答的开放问题。尚无儿童或青少年试验注册。
• As of the 2026 updates, both trials were active, with SERONCO-1 still running in Barcelona and SERHEMA-1 recruiting in Spain and Austria, and no efficacy claims have been made for either. The company's stated ambition is to move from dose finding into efficacy cohorts in the most responsive diseases, a transition that the phase 1/2 design of SERHEMA-1 anticipates. Interim communication has focused on pharmacokinetics rather than on tumour responses, which is normal for a dose-escalation programme. Any statement about clinical benefit would be premature at this stage.截至 2026 年更新，两项试验均在活跃状态，SERONCO-1 仍在巴塞罗那运行，SERHEMA-1 在西班牙与奥地利招募，两者均无疗效主张。公司既定目标是从剂量寻找推进到最敏感疾病中的疗效队列，SERHEMA-1 的 1/2 期设计已为此预留空间。过渡性沟通聚焦药代动力学而非肿瘤缓解，这对剂量爬坡项目属正常。在此阶段任何关于临床获益的表述都为时过早。

Adverse effects

• No adverse-event rates have been published for AOP208, because both trials are in early phases and detailed safety results have not been disclosed. The first-in-human presentation at the 2026 congress focused on pharmacokinetics, reporting dose-dependent exposure without plateau and no emerging tolerability signal that would stop escalation. The company's public communication states that preclinical data and early clinical safety data demonstrate the potential for further development, without quantifying events. Until a peer-reviewed safety report appears, the compound's human toxicity profile is uncharacterized.AOP208 尚未公布不良反应发生率，因为两项试验均处于早期阶段，详细安全性结果未披露。2026 年年会上的首次人体报告聚焦药代动力学，报告暴露呈剂量依赖且未见平台，且无新出现的耐受性信号阻止爬坡。公司公开沟通称临床前数据与早期临床安全性数据显示了进一步开发的潜力，但未对事件量化。在同行评审安全性报告出现前，该化合物的人体毒性特征属未表征。
• The theoretical safety consideration that follows from the mechanism is serotonin-system pharmacology, since the 5-HT1B receptor is a presynaptic autoreceptor in the normal nervous system and its systemic blockade could produce cardiovascular or central effects. The programme's premise is that the receptor adopts a distinct conformation in cancer cells, so a blocker tuned to that conformation would spare normal signalling, but this selectivity has not been demonstrated clinically. The oral route and the oncology setting mean that patients are monitored under trial-specific rules rather than under any label guidance. No dose-limiting toxicity has been announced.从机制推出的理论安全性考量是 5-羟色胺系统药理学，因为 5-HT1B 受体是正常神经系统的突触前自身受体，其全身阻断可能产生心血管或中枢效应。该项目的前提是该受体在癌细胞中呈独特构象，因此调谐至该构象的阻断剂可豁免正常信号传导，但该选择性尚未获临床证明。口服途径与肿瘤情境意味着患者按试验特定规则而非标签指导监测。尚未公布剂量限制毒性。
• Preclinical safety was the basis for advancing the compound into humans, and the trial protocols apply the standard early-phase framework: defined laboratory entry thresholds, dose-modification rules and stopping criteria. Because the target is expressed in normal tissues, the escalation is deliberately gradual, with the pharmacokinetic profile monitored at each level to confirm the exposure target. The myelodysplastic and leukaemia population of SERHEMA-1 brings baseline cytopenias that complicate toxicity attribution, a common challenge in haematological early-phase trials. No maximum tolerated dose has been reported.临床前安全性是该化合物进入人体的基础，试验方案适用标准早期框架：既定的实验室入组界值、剂量调整规则与停药标准。由于靶点在正常组织中表达，爬坡刻意渐进，每一水平监测药代动力学特征以确认暴露目标。SERHEMA-1 的骨髓增生异常与白血病人群带有基线血细胞减少，使毒性归因复杂化，这是血液学早期试验的常见难题。尚未报告最大耐受剂量。
• Interaction liability has not been characterized, and neither protocol has published a formal drug-interaction study. Patients in both trials are managed under protocol-specific rules for concomitant medications, as is standard when a compound's metabolic routes are unknown. The haematological setting adds polypharmacy, since patients with relapsed leukaemia often take supportive and anti-infective agents, and the trial rules govern those combinations. No food or beverage interaction has been reported for the compound. The absence of a plateau in exposure suggests that metabolism is not saturating at the tested doses.相互作用风险尚未表征，两项方案均未发表正式药物相互作用研究。两项试验的患者按方案特定规则管理合并用药，这在化合物代谢途径未知时属标准做法。血液学情境带来多重用药，因为复发白血病患者常服用支持性与抗感染药物，试验规则管辖这些联合。尚未报告该化合物的食物或饮料相互作用。暴露未见平台提示在所测试剂量下代谢未达饱和。

Contraindications and interactions

• No contraindications can be listed for an investigational agent with no approved label, and neither trial protocol defines contraindications in the label sense. The protocols instead apply the standard early-phase exclusions: inadequate organ function, uncontrolled intercurrent illness, and performance-status or life-expectancy limits that are typical for phase 1 oncology studies. Because the compound acts on a serotonin receptor, concomitant use of serotonergic drugs is a theoretical concern, but no formal interaction data exist and the protocols manage co-medication through their general rules. No food or beverage interaction has been characterized.对于无获批标签的在研药物无法列出禁忌，两项试验方案均未以标签意义定义禁忌。方案代之以标准早期排除标准：器官功能不足、不受控制的伴随疾病，以及 1 期肿瘤研究典型的体能状态或预期寿命限制。由于该化合物作用于 5-羟色胺受体，合并使用 5-羟色胺能药物是理论关切，但无正式相互作用数据，方案通过一般规则管理合并用药。尚无食物或饮料相互作用表征。
• Normal-tissue expression of the 5-HT1B receptor raises the theoretical possibility of cardiovascular interactions, since serotonin signalling participates in vascular tone, but no clinical cardiovascular signal has been reported for AOP208. The programme's answer to normal-tissue risk is the cancer-cell conformation hypothesis rather than a contraindication framework, and that hypothesis remains unproven in humans. Trial protocols include the usual cardiac monitoring appropriate to first-in-human studies. Whether any formal contraindication will be defined can only be judged after the safety profile is published.5-HT1B 受体在正常组织的表达提出了心血管相互作用的理论可能，因为 5-羟色胺信号参与血管张力，但 AOP208 尚无临床心血管信号报告。该项目对正常组织风险的回答是癌细胞构象假说而非禁忌框架，而该假说尚未在人体证明。试验方案包含首次人体研究适用的常规心脏监测。是否会定义任何正式禁忌，只有在安全性特征公布后才能判断。
• The haematological trials add a specific practical consideration: patients with relapsed acute myeloid leukaemia or high-risk myelodysplastic syndrome often have baseline cytopenias and organ compromise from prior therapy, so the protocol's entry thresholds protect residual marrow and organ function. Concomitant anti-infective and supportive agents are common in this population and are handled under protocol rules rather than through published interaction data. Because the compound is oral, absorption problems from mucositis are a practical tolerability issue in leukaemia patients. No dose adjustment for hepatic or renal impairment has been defined.血液学试验增加了一个具体的实际考量：复发急性髓系白血病或高危骨髓增生异常综合征患者常有既往治疗导致的基线血细胞减少与器官受损，因此方案的入组界值保护残余骨髓与器官功能。该人群中常见的合并抗感染与支持药物按方案规则处理，而非依据已发表的相互作用数据。由于该化合物口服，黏膜炎导致的吸收问题是白血病患者的实际耐受性问题。尚未定义肝肾功能受损的剂量调整。

Pharmacology

• The pharmacological target is the serotonin 1B receptor, also written 5-HT1B or HTR1B, a G-protein-coupled receptor that in the normal nervous system acts as a presynaptic autoreceptor inhibiting serotonin release and participates in vascular tone. In cancer cells the receptor is reported to adopt a particular conformation that controls metabolic pathways whose blockade may be crucial for tumour initiation and development, and AOP208 is described as blocking that conformation. The claim of first-in-class status rests on the fact that no serotonin receptor had previously been exploited as a cancer target. The preclinical basis was established in leukaemic stem cells, where the receptor was shown to be key to survival.药理学靶点是 5-羟色胺 1B 受体（亦写作 5-HT1B 或 HTR1B），一种在正常神经系统中充当突触前自身受体抑制 5-羟色胺释放并参与血管张力的 G 蛋白偶联受体。在癌细胞中，该受体据报呈特定构象，控制着其阻断可能对肿瘤发生与发展至关重要的代谢通路，AOP208 被描述为阻断该构象。首创地位的主张立于此前从未有 5-羟色胺受体被用作癌症靶点这一事实。临床前依据在白血病干细胞中确立，该受体在那里被证明对存活至关重要。
• The therapeutic hypothesis is cancer-stem-cell directed: leukaemic stem cells are responsible for disease initiation, maintenance and relapse, so a drug that removes their survival mechanism could in principle delay or prevent relapse even if it does not shrink the disease immediately. The same logic is extended to the tumour microenvironment in the bone marrow niche, where the receptor is proposed to support treatment resistance. In solid tumours the analogous claim is that blocking the receptor in cancer stem cells removes a survival and resistance mechanism. This stem-cell framing distinguishes the programme from conventional cytotoxic approaches and explains its slow, dose-finding cadence.治疗假说面向癌症干细胞：白血病干细胞负责疾病的发生、维持与复发，因此移除其存活机制的药物原则上可延迟或预防复发，即使它不能立即缩小疾病。同一逻辑扩展到骨髓龛中的肿瘤微环境，受体在那里被提议支持治疗耐药。在实体瘤中，类似的论断是阻断癌症干细胞中的受体可移除一种存活与耐药机制。这种干细胞框定把该项目与常规细胞毒方法区分开来，也解释了其缓慢的剂量寻找节奏。
• The receptor's role in cancer cells was established through work at the Josep Carreras Leukaemia Research Institute from 2012 onwards, with peer-reviewed publications documenting that the serotonin 1B receptor is key to the process in leukaemic stem cells. Follow-up work characterized the receptor's function in cancer-cell survival and resistance pathways. Those studies provide the scientific basis for the first-in-human programme, and both are cited in the sponsor's trial communications. No mechanism-of-action study of AOP208 itself, as opposed to the receptor, has been published.该受体在癌细胞中的作用通过 Josep Carreras 白血病研究所自 2012 年起的工作确立，同行评审发表记录了 5-羟色胺 1B 受体对白血病干细胞中该过程的关键性。后续研究刻画了该受体在癌细胞存活与耐药通路中的功能。这些研究为首次人体项目提供科学基础，两者均被申办方的试验通讯引用。除受体之外，尚未发表 AOP208 本身的作用机制研究。^[2][3]
• Because the target is a conformation rather than the receptor as such, the pharmacology is unusual: the compound does not simply antagonize 5-HT1B signalling everywhere, but is tuned to the cancer-cell conformation, which is why normal serotonergic function is expected to be largely spared. That selectivity claim is the programme's scientific core and its main risk, since conformational selectivity is harder to demonstrate than classical target engagement. No binding or selectivity data for AOP208 have been published in the peer-reviewed literature. The pharmacokinetic programme is therefore the only public window into the compound's behaviour so far.由于靶点是一种构象而非受体本身，其药理学不同寻常：该化合物不是在所有地方简单拮抗 5-HT1B 信号，而是调谐至癌细胞构象，这就是预期正常 5-羟色胺功能基本不受影响的原因。该选择性主张是项目的科学核心也是主要风险，因为构象选择性比经典靶点接合更难证明。AOP208 的结合与选择性数据尚未在同行评审文献中发表。因此药代动力学项目是目前窥见该化合物行为的唯一公开窗口。
• Pharmacokinetics are the best-characterized aspect of the compound in humans: the 2026 interim report described dose-dependent exposure without plateau, supporting continued dose escalation, and the schedule is oral administration. The absence of a plateau indicates that exposure keeps rising with dose in the tested range, so the maximum tolerated dose has not yet been reached at the reported levels. No half-life, bioavailability, metabolism or excretion values have been published. The solid-tumour and leukaemia trials will in principle generate the formal pharmacokinetic parameters needed for dose selection.药代动力学是该化合物在人体中特征刻画最充分的方面：2026 年过渡性报告描述暴露呈剂量依赖且未见平台，支持继续剂量爬坡，给药方式为口服。未见平台表明在所测范围内暴露随剂量持续上升，因此在报告水平上尚未达到最大耐受剂量。尚未公布半衰期、生物利用度、代谢或排泄数值。实体瘤与白血病试验原则上将产生剂量选择所需的正式药代动力学参数。
• The downstream pharmacological consequences of receptor blockade in cancer cells are metabolic: the sponsor's communication describes pathways whose blockade may be crucial for tumour cell survival and treatment resistance, without naming the pathways in the public releases. In leukaemic stem cells the receptor's key role was established experimentally, and the clinical programme tests whether that role translates into a therapeutic effect in patients. The bone marrow niche framing adds a microenvironment dimension, since the receptor is proposed to act in the niche that shelters leukaemic stem cells. No pharmacodynamic marker has been validated for clinical use.癌细胞中受体阻断的下游药理学后果是代谢性的：申办方沟通描述了其阻断可能对肿瘤细胞存活与治疗耐药至关重要的通路，但公开新闻稿未点名这些通路。在白血病干细胞中，该受体的关键作用已经实验确立，临床项目检验该作用能否转化为患者中的治疗效果。骨髓龛框定增加了微环境维度，因为受体被提议在庇护白血病干细胞的龛中起作用。尚无经验证可供临床使用的药效学标志物。

Chemistry

• AOP208 is a small molecule designed for oral administration, the product of a chemical development programme at Leukos Biotech that selected it from a generated compound library. Its chemical structure, formula and molecular weight have not been disclosed in the public trial documentation, and no PubChem, ChEMBL, KEGG or DrugBank record is publicly linked to the development code. The compound is identified in the literature by its codes AOP208, LB-208 and LB208 and by a Wikidata item, rather than by structural data. This opacity is normal for a small company's first-in-class asset ahead of patent publication or journal disclosure.AOP208 是一种为口服给药设计的小分子，出自 Leukos Biotech 从其生成的化合物库中选出该分子的化学开发项目。其化学结构、分子式与分子量未在公开试验文件中披露，且没有与研发代号关联的公开 PubChem、ChEMBL、KEGG 或 DrugBank 记录。该化合物在文献中以代号 AOP208、LB-208 与 LB208 及一个 Wikidata 条目标识，而非结构数据。这种不透明对小公司首创资产在专利公布或期刊披露前属正常。
• The lack of public structural data means that no salt forms, stereochemistry or formulation details can be described, and the compound's physicochemical properties are unknown outside the company. The oral route implies acceptable absorption and metabolic stability, but no values have been published. The sponsor describes the molecule as the product of a chemical development programme rather than of a screening hit alone, implying medicinal-chemistry optimization. Any structural disclosure would most likely accompany a journal publication or a patent grant, neither of which has occurred for the clinical candidate as of the latest updates.缺乏公开结构数据意味着无法描述盐型、立体化学或处方细节，该化合物的理化性质在公司外不为人知。口服途径暗示可接受的吸收与代谢稳定性，但无数值发表。申办方将该分子描述为化学开发项目的产物而非单纯筛选命中，暗示经过药物化学优化。任何结构披露最可能伴随期刊发表或专利授权，而截至最新更新，该临床候选两者均未发生。
• For a compound of this kind, the relevant chemistry question is conformational selectivity rather than classical potency: the molecule must distinguish the cancer-cell conformation of the receptor from the normal one, a property that cannot be inferred from structure alone. No binding assays, selectivity panels or structure-activity series have been published for AOP208. The compound library generated during the selection programme remains the property of the partners under the 2022 agreement, and backup compounds may exist within it. Whether any of them will be disclosed depends on the programme's progress.对这类化合物而言，相关的化学问题是构象选择性而非经典效价：分子必须区分受体的癌细胞构象与正常构象，这一性质无法单从结构推断。AOP208 尚无结合实验、选择性面板或构效系列发表。选择项目期间生成的化合物库按 2022 年协议归合作方所有，其中可能存在备份化合物。其中任何一个是否会披露，取决于项目的进展。

Society and culture

• AOP208 has no regulatory status in any country, does not appear on the WHO Model List of Essential Medicines and has no ATC code, which is expected for a first-in-human compound. Its development is notable as an example of a small Austrian rare-disease company, AOP Health, building a first-in-class oncology programme on licensed academic science, with public Spanish funding sharing the early risk. The company's roots date to 1996 and its portfolio spans rare diseases and intensive care, so AOP208 represents a strategic diversification into oncology. The programme's narrative of attacking cancer stem cells through a serotonin receptor has been the centre of its conference presentations.AOP208 在任何国家均无监管地位，未出现在 WHO 基本药物示范清单上，也没有 ATC 编码，这对首次人体化合物属预期。其开发的值得注意之处在于，它示范了一家奥地利罕见病小公司 AOP Health 如何在授权的学术科学上建立首创肿瘤项目，并由西班牙公共资金分担早期风险。该公司渊源可追溯至 1996 年，产品线横跨罕见病与重症医学，因此 AOP208 代表了向肿瘤学的战略多元化。通过 5-羟色胺受体攻击癌干细胞的纲领性叙事，是其会议报告的中心。
• The first-in-class framing carries reputational weight: AOP Health describes the approach as a new therapeutic concept for challenging blood cancers and notes that the target had not previously been exploited in cancer therapy. Independent coverage has treated the programme as a rare example of a cancer stem-cell therapy reaching human trials through a receptor target rather than through a cell-surface differentiation antigen. The Barcelona research institute's role gives the programme a public-research pedigree that features in its communications. No independent evaluation of the compound's prospects has been published, and analysts have made no efficacy projections.首创框定带有声誉分量：AOP Health 将该方法描述为针对棘手血液肿瘤的新治疗概念，并指出该靶点此前未在癌症治疗中被利用。独立报道把该项目视为癌症干细胞疗法通过受体靶点（而非细胞表面分化抗原）进入人体试验的罕见例子。巴塞罗那研究所的角色赋予该项目公共研究血统，这在其沟通中占据显著位置。尚无对该化合物前景的独立评价发表，分析人士亦未作疗效预测。
• The Spanish public-private funding structure, grant CPP2021-008715 under the RETOS collaboration programme, is itself a marker of how early oncology assets are financed in Europe, with ministry money de-risking a trial that a small biotech could not fund alone. The Vall d'Hebron early-phase unit's role as the world's only SERONCO-1 site concentrates both the science and the reputational risk in one institution. AOP Health's control of global rights outside mainland China means that any future approval would be an Austrian-sponsored product in most markets. The compound has no established brand name, and no tradename has been announced.西班牙公私资助结构（RETOS 合作计划下的 CPP2021-008715 拨款）本身即是欧洲早期肿瘤资产如何融资的标志，部里资金为一家小生物技术公司无法独自资助的试验降险。Vall d'Hebron 早期单元作为全球唯一 SERONCO-1 站点的角色，把科学与声誉风险集中于同一机构。AOP Health 对中国大陆以外全球权利的控制意味着，未来任何获批在多数市场都将是奥地利申办的产品。该化合物没有既定商品名，亦未宣布商标名。

Availability and economics

• The compound is not commercially available anywhere and is supplied only through the two registered trials, SERONCO-1 at the Vall d'Hebron Institute of Oncology in Barcelona and SERHEMA-1 at specialized centres in Spain and Austria. There is no list price, no reimbursement status and no generic or biosimilar landscape, because no market authorization exists. Access is therefore limited to trial participants at a handful of academic centres, and the planned enrolments of 57 and 60 patients cap the total exposed population in these studies. No expanded-access or compassionate-use pathway exists.该化合物在任何地方均无商业供应，仅通过两项注册试验提供：SERONCO-1 在巴塞罗那 Vall d'Hebron 肿瘤研究所，SERHEMA-1 在西班牙与奥地利的专门中心。由于不存在市场授权，没有挂牌价格、没有报销状态，也没有仿制药或生物类似药格局。因此可及性仅限于少数研究中心的试验受试者，57 例与 60 例的计划入组限制了这些研究中的总暴露人群。不存在扩大可及或同情使用途径。
• No pricing, cost-effectiveness or health-technology-assessment data exist, and none can exist before an approval decision. Development costs are shared between the companies, with the Spanish ministry grant covering part of the Barcelona trial, a structure that keeps the disclosed cash requirement modest relative to a pharmaceutical-run programme. The 2022 licence agreement gave AOP Health exclusive commercial rights in most markets, so any future economics would flow to the Austrian company, with Leukos Biotech retaining rights for mainland China. No milestone or royalty terms have been disclosed.不存在定价、成本效果或卫生技术评估数据，在获批决定前也不可能存在。开发成本由两家公司分担，西班牙部里拨款覆盖巴塞罗那试验的一部分，这一结构使披露的现金需求相对于制药公司运行的项目保持适中。2022 年许可协议使 AOP Health 获得多数市场的独家商业权利，因此未来任何经济性将流向这家奥地利公司，Leukos Biotech 保留中国大陆权利。尚未披露里程碑或特许权使用费条款。
• The commercial case, if the programme succeeds, rests on the first-in-class position in a target with no competing agents, which would give any approved product a period of market exclusivity grounded in mechanism rather than in patent term alone. The leukaemia and myelodysplastic settings offer smaller populations but faster paths and higher unmet need, while the solid-tumour cohorts represent the larger long-term prize. For patients, the practical consequence today is that access is confined to two trials at a few centres, principally in Spain. No patient organization or advocacy group specific to the compound exists, and none has commented publicly.若项目成功，商业案例立于首创地位——该靶点没有竞争药物，任何获批产品都将获得一段基于机制而非仅基于专利期的市场独占期。白血病与骨髓增生异常情境人群较小但路径更快、未满足需求更高，而实体瘤队列代表更大的长期奖池。对患者而言，当前的实际结果是可及性仅限于少数中心（主要在西班牙）的两项试验。不存在针对该化合物的患者组织或倡导团体，亦无公开评论。